Skip to main content
Research_

Drug Discovery Initiative

Innovative drug discovery to support better health outcomes
A dynamic and interdisciplinary network that brings together the best people, technologies and tools to enable early stage drug discovery research.

Our initiative focuses on designing and developing innovative tools and techniques to identify novel therapeutic targets, delivery mechanisms, and bioactive molecules with high potential for industry uptake and clinical translation.

It is built on collective expertise in drug discovery research from across the University, underpinned by state-of-the-art infrastructure and input from industry and clinical advisory groups.

The Drug Discovery Initiative is supported by its team, members, and partners, underpinned by the University of Sydney’s Research Portfolio.

We are a point of contact for internal researchers looking to connect with complementary capability in the area of drug discovery research, or for external stakeholders looking to engage with our researchers.

Our initiatives

The Drug Discovery Initiative facilitates and enables research at the University by:

  • Funding innovative research programs across our five disease focus areas
  • Helping our members to identify and connect with collaborators from the University and industry
  • Hosting conferences and events with representatives from the University, industry, and healthcare
  • Providing specialised technical support for drug discovery within Sydney Analytical

Our management team

Academic Director
Professor Michael Kassiou
Phone: +61 2 9351 2745
Email: michael.kassiou@sydney.edu.au

Executive Officer
Anna Renfrew
Phone: +61 2 9114 4246
Email: anna.renfrew@sydney.edu.au

Executive Officer
Julia Ning
Phone: +61 2 9114 4246
Email: julia.ning@sydney.edu.au

The DDI works closely with a number of Centres and Initiatives with representation on our Internal Management Group

Management group members

Upcoming events

Stay up to date with new and upcoming events by joining our newsletter mailing list

Read the most recent edition: April 2020

News